Clinical medication guidance for hypertension personalization through pharmacogenomic research and analysis

Most hypertensive patients in the Beijing region carry a high frequency of CYP2D6 * 10, ADRB1(1165 G>C), and <i>ACE I/D</i> genes, implying that they might be more sensitive to β-blockers, potentially benefitting more from ACEI drugs. The high allele frequencies of CYP2D6 * 10, ADRB1(1165 G>C), and <i>ACE I/D</i> in Beijing hypertensive patients indicate enhanced sensitivity to β-blockers and good therapeutic response to ACE inhibitors. Therefore, clinicians need to account for these factors when prescribing the aforementioned medications.